Lomiko Metals (LMRMF) & Opiant Pharmaceuticals (OPNT) Critical Survey

Lomiko Metals (OTCMKTS:LMRMF) and Opiant Pharmaceuticals (NASDAQ:OPNT) are both small-cap basic materials companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, earnings, dividends, profitability and risk.


This table compares Lomiko Metals and Opiant Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Lomiko Metals N/A -130.32% -127.08%
Opiant Pharmaceuticals -93.66% -93.00% -60.06%

Risk & Volatility

Lomiko Metals has a beta of 1.93, suggesting that its share price is 93% more volatile than the S&P 500. Comparatively, Opiant Pharmaceuticals has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500.

Valuation & Earnings

This table compares Lomiko Metals and Opiant Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Lomiko Metals N/A N/A -$4.34 million N/A N/A
Opiant Pharmaceuticals $13.98 million 3.44 -$21.19 million ($7.10) -1.73

Lomiko Metals has higher earnings, but lower revenue than Opiant Pharmaceuticals.

Institutional & Insider Ownership

19.6% of Opiant Pharmaceuticals shares are held by institutional investors. 37.9% of Opiant Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Lomiko Metals and Opiant Pharmaceuticals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lomiko Metals 0 0 0 0 N/A
Opiant Pharmaceuticals 0 0 1 0 3.00

Opiant Pharmaceuticals has a consensus target price of $42.00, suggesting a potential upside of 242.66%. Given Opiant Pharmaceuticals’ higher possible upside, analysts plainly believe Opiant Pharmaceuticals is more favorable than Lomiko Metals.


Opiant Pharmaceuticals beats Lomiko Metals on 7 of the 10 factors compared between the two stocks.

Lomiko Metals Company Profile

Lomiko Metals Inc., an exploration stage company, engages in the acquisition, exploration, and development of resource properties in Canada. The company primarily explores for graphite deposits. The company holds 100% interests in the Vines Lake zinc-silver-gold property, which consists of three claims covering an area of approximately 1,209.84 hectares located in Liard Mining District of British Columbia; the Quatre-Milles graphite property located north of Sainte-Veronique, Quebec; and the Quatre-Milles West located in southern Quebec. It also holds a 40% interest in the La Loutre graphite property covering an area of approximately 2,508.97 hectares located in southern Québec; and 80% interest in the Lac-des-Iles property covering an area of approximately 5,601.30 hectares situated in Québec. The company was formerly known as Lomiko Resources Inc. and changed its name to Lomiko Metals Inc. in October 2008. Lomiko Metals Inc. was incorporated in 1987 and is headquartered in Surrey, Canada.

Opiant Pharmaceuticals Company Profile

Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine. Opiant Pharmaceuticals, Inc. has a collaboration agreement with Titan Pharmaceuticals, Inc. to explore development of a novel approach to the prevention of opioid relapse and overdose in individuals with opioid use disorder. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Santa Monica, California. Opiant Pharmaceuticals, Inc. is a subsidiary of Pelikin Group.

Receive News & Ratings for Lomiko Metals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lomiko Metals and related companies with MarketBeat.com's FREE daily email newsletter.